Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Treasury Shares (2021 - 2025)

Historic Treasury Shares for CytomX Therapeutics (CTMX) over the last 5 years, with Q3 2025 value amounting to $2.9 million.

  • CytomX Therapeutics' Treasury Shares rose 5999.64% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 5999.64%. This contributed to the annual value of $1.9 million for FY2024, which is 3232.37% up from last year.
  • As of Q3 2025, CytomX Therapeutics' Treasury Shares stood at $2.9 million, which was up 5999.64% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Treasury Shares registered a high of $2.9 million during Q3 2025, and its lowest value of $868250.0 during Q4 2021.
  • For the 5-year period, CytomX Therapeutics' Treasury Shares averaged around $1.7 million, with its median value being $1.6 million (2023).
  • The largest annual percentage gain for CytomX Therapeutics' Treasury Shares in the last 5 years was 7230.38% (2023), contrasted with its biggest fall of 263.67% (2023).
  • Quarter analysis of 5 years shows CytomX Therapeutics' Treasury Shares stood at $868250.0 in 2021, then skyrocketed by 39.69% to $1.2 million in 2022, then increased by 15.47% to $1.4 million in 2023, then skyrocketed by 32.32% to $1.9 million in 2024, then skyrocketed by 56.74% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $2.9 million for Q2 2025, and $2.8 million during Q1 2025.